Check the outcome.

Phase 2 trials often rely on surrogates for overall survival, most commonly overall response rate (ORR) in those evaluating checkpoint inhibitors. So it’s a shame ORR is actually pretty poorly correlated with OS and that progression-free survival at 6 months is much better.